MARKET

NEUP

NEUP

Neuphoria Therapeutics Inc
NASDAQ
4.730
-0.360
-7.07%
After Hours: 4.750 +0.02 +0.42% 17:17 05/15 EDT
OPEN
5.10
PREV CLOSE
5.09
HIGH
5.10
LOW
4.665
VOLUME
79.66K
TURNOVER
--
52 WEEK HIGH
21.40
52 WEEK LOW
3.645
MARKET CAP
25.50M
P/E (TTM)
-2.2306
1D
5D
1M
3M
1Y
5Y
1D
Deal Dispatch: GoPro Retains Houlihan Lokey In Strategic Review, Brookfield Buys World Freight Company, YesCare Corp. Bankruptcy
Benzinga · 11h ago
Neuphoria Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
TipRanks · 11h ago
Neuphoria Therapeutics Cut to Neutral From Buy by HC Wainwright & Co.
Dow Jones · 12h ago
HC Wainwright & Co. Downgrades Neuphoria Therapeutics to Neutral
Benzinga · 12h ago
Neuphoria Therapeutics Q3 EPS $(0.09) Beats $(0.97) Estimate
Benzinga · 16h ago
Weekly Report: what happened at NEUP last week (0504-0508)?
Weekly Report · 4d ago
Weekly Report: what happened at NEUP last week (0427-0501)?
Weekly Report · 05/04 10:11
Weekly Report: what happened at NEUP last week (0420-0424)?
Weekly Report · 04/27 10:13
More
About NEUP
Neuphoria Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. Its lead drug candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute, as-needed treatment of social anxiety disorder and for the chronic treatment of post-traumatic stress disorder. BNC210 is a well-tolerated, broad-spectrum antianxiety experimental therapeutic, designed to restore neurotransmitter balance in relevant brain areas, providing rapid relief from stress and anxiety symptoms without the common pitfalls of sedation, cognitive impairment, or addiction. In addition, the Company has two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions.

Webull offers Neuphoria Therapeutics Inc stock information, including NASDAQ: NEUP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NEUP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NEUP stock methods without spending real money on the virtual paper trading platform.